CDH1 and neoplasm: We evaluated the relationship of E-cadherin expression with (i) patients’ overall survival (OS) and progression-free survival (PFS); (ii) patients’ FIGO stage and grade, as well as the histopathological type (HP) of the tumor; and (iii) as a potential parameter helping to discriminate malignant and nonmalignant ovarian tumors.